Pharmafile Logo
Pharmafocus logo
Advanced Search

Xultophy

Showing 4 posts of 4 posts found.

novo_flag

Novo Nordisk unveils hard-hitting data for two of its diabetes therapies

December 5, 2017
Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma

Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …

News

Novo’s Xultophy beats basal insulin in cutting cardiovascular risk

September 14, 2017
Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …

News
fdaoutsideweb

Sanofi and Novo to face off in diabetes sphere following FDA approvals

November 22, 2016
Manufacturing and Production, Sales and Marketing FDA, Novo Nordisk, Sanofi, Soliqua, Xultophy, diabetes

Sanofi and Novo are set to face off in the diabetes market after the FDA approved combination treatments from the …

News
novo_nordisk

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016
Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026